MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies Poster will present characterization of metabolites produced by MaaT034 and its immunomodulatory effects on host cells. The new data strengthens previous promising findings shared at the Society for Immunotherapy of Cancer (SITC) conference in November 2023 and [...]
MaaT Pharma Announces Long Term Follow-Up Data for MaaT013 in Early Access Program to be Presented at the Upcoming EBMT Conference Oral presentation will highlight new data in Early Access Program (EAP) for patients with acute Graft-vs-Host Disease (aGvHD) treated with MaaT013. This is the seventh year that MaaT Pharma's abstracts have been chosen for [...]
MaaT Pharma: Monthly Information Regarding the Total Number of Voting Rights and Shares Comprising the Share Capital Article 223-16 of the General Regulations of the Financial Markets Authority (AMF - Autorité des Marchés Financiers) Lyon, France, March 7, 2024 –6:10pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a [...]
MaaT Pharma Releases its 2024 Financial Calendar Lyon, France, March 7, 2024 –6:00pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotech company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, releases its 2024 financial calendar*: March 28, 2024: Publication [...]
MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma Last patient randomized in Phase 2a PICASSO trial, sponsored by AP-HP in collaboration with MaaT Pharma, INRAE and Institut Gustave Roussy, evaluating MaaT013 in melanoma in combination with Immune [...]
MaaT Pharma To Present New Preclinical Data at AACR for MaaT034 Aiming To Improve Patients’ Responses to Immunotherapies Poster will present characterization of metabolites produced by MaaT034 and its immunomodulatory effects on host cells. The new data strengthens previous promising findings shared at the Society for Immunotherapy of Cancer (SITC) conference in November 2023 and [...] 
